We are live on
!
Find out more
Intellia Therapeutics
NTLA
NTLA
291 hedge funds and large institutions have $938M invested in Intellia Therapeutics in 2025 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 97 increasing their positions, 87 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
44% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $23.4M
40% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 48
11% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 87
3% more funds holding
Funds holding: 282 → 291 (+9)
7.1% less ownership
Funds ownership: 97.05% → 89.95% (-7.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
48% less capital invested
Capital invested by funds: $1.8B → $938M (-$861M)
Holders
291
Holders Change
+9
Holders Change %
+3.19%
% of All Funds
3.54%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.02%
New
67
Increased
97
Reduced
87
Closed
48
Calls
$33.7M
Puts
$23.4M
Net Calls
+$10.3M
Net Calls Change
-$20.1M
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
+$42.7M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$31.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$19.9M |
| 5 |
Renaissance Technologies
New York
|
+$14.1M |
Top Sellers
| 1 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
-$71.2M |
| 2 |
Morgan Stanley
New York
|
-$50.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$47.4M |
| 4 |
Goldman Sachs
New York
|
-$38.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.5M |
